Review highlights linezolid's role in tackling multidrug-resistant TB and extensively drug-resistant TB, suggesting significant clinical implications.
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a significant global health issue, responsible for over 1.4 million deaths annually. The emergence of drug-resistant strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses a major challenge to effective treatment and control. This review aims to explore the development and progress of novel oxazolidinone antibiotics, which have shown promise against these resistant strains. By inhibiting bacterial protein synthesis, oxazolidinones like linezolid have demonstrated efficacy against MDR-TB and XDR-TB. This review briefly outlines the pharmacological and resistance mechanisms of currently mainstream ant tuberculosis drugs. Also, it examines the pharmacological mechanisms, clinical significance, research status, and future potential of oxazolidinone compounds in combating drug-resistant tuberculosis, hoping to address the urgent need for new and effective treatment options.
No takes yet. Share an insight, caveat, or question.
Tao Li (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: